FierceBiotech reports that: "2007 may well go down as the year that Big Pharma went beyond merely embracing biotechnology and decided that now was the time to marry up with the new technology. With Big Pharma's accountants totting up the last big rewards from a slew of blockbusters, biotech was seen at the next big thing in therapeutics, and companies were willing to spend big to get in the act."
FierceBiotech expects the unmistakable surge in deal-making (in 2007) between Big Pharma and biotechnology (through mergers, collaborative risk-sharing, joint ventures and other co-development and co-promotion arrangements) to continue in 2008.
